Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: A randomized, controlled trial

Annals of Internal Medicine

Volumn 135, Issue 6, 2001, Pages 412-422

  Boogaerts, M ^a   Winston, D J ^a   Bow, E J ^a   Garber, G ^a   Reboli, A C ^a   Schwarer, A P ^a   Novitzky, N ^a   Boehme, A ^a   Chwetzoff, E ^a   De Beule, K ^a   Arthur, C ^a   Lechner, K ^a   Linkesch, W ^a   Waldner, R ^a   Bosly, A ^a   Crokaert, F ^a   Maertens, J ^a   Michaux, J ^a   Noens, L ^a   Schroyens, W ^a   Van Hoof, A ^a   Fong, I ^a   Keating, A ^a   Laverdiere M ^a   McGeer, A ^a   Nantel, S ^a   Rotstein, C ^a   Schlech, W ^a   Smaill, F ^a   Cassassus, P ^a   Fenaux, P ^a   Francois, S ^a   Herbrecht, R ^a   Ifrah, N ^a   Pris, J ^a   Mounier, C ^a   Nedellec, G ^a   Oriol, P ^a   Rieux, C ^a   Stamatoullas, A ^a   Vernant, J ^a   Witz, B ^a   Goldschmidt, H ^a   Pfreundschuh, M ^a   Schuler, U ^a   Daenen, S ^a   Dekker, A ^a   Kramer, M ^a   Van Marwijk Kooy, M ^a   Blundell, E ^a   Milligan, D ^a   Morgenstern, G ^a   Pagliuca, A ^a   Prentice, H ^a   Rule, S ^a   Schey, S ^a   Anaissie, E ^a   Arnow, P ^a   Blummer, J ^a   Martin, M ^a   Territo, M ^a   Wingard, J ^a   Burzykowski, T ^a   Molenberghs, G ^a   Cuijpers, A ^a   Van Hoof, I ^a   Vertommen, C ^a   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ITRACONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035909054     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-135-6-200109180-00010     Document Type: Article

References (27)

1. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia
2. Empiric antifungal therapy in febrile granulocytopenic patients
3. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: A pragmatic, multicentre, prospective and randomised clinical trial
4. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients
5. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
6. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia
7. Invasive fungal infections in patients receiving intensive cytotoxic therapy for cancer
8. Fungal infections in cancer patients: An international autopsy survey
9. Clinical experience with amphotericin B in acute myelogenous leukemia
10. Clinical value of empirical amphotericin B in patients with acute myelogenous leukemia
11. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
12. Pretreatment regimens for adverse events related to infusion of amphotericin B
13. Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature
14. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study
15. Randomised multicentre trial of intravenous fluconazole versus intravenous amphotericin B in neutropenic febrile patients
16. National surveillance of nosocomial blood stream infection due to Candida albicans. frequency of occurrence and antifungal susceptibility in the SCOPE Program
17. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans. frequency of occurrence and antifungal susceptibility in the SCOPE Program
18. Organism-dependent fungicidal activities of azoles
19. In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus
20. Antifungal prophylaxis with itraconazole in prolonged neutropenia: Correlation with plasma levels
21. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients
22. Serum concentrations of itraconazole in neutropenic patients receiving itraconazole/cyclodextrin solution
23. Prediction of creatinine clearance from serum creatinine
24. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
25. Response to empiric amphotericin B during antileukemic therapy-induced granulocytopenia
26. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections
27. Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy